By Hilary Rosselot
Healx Updates the Fragile X Community About their Fragile X Program and the IMPACT-FXS trial
Healx shares the closing of their IMPACT-FXS trial with plans to open a new study in early 2023.
Read the full letter to understand the shift in their plans and what to expect: Community statement – Update on IMPACT-FXS
Healx continues to work extensively with the NFXF’s Clinical Trials Committee within the Research Readiness Program to be sure their Fragile X program is scientifically-sound, relevant, and impactful.
Thanks, Healx, for your open and honest communication with the Fragile X community! We look forward to sharing your new study in 2023!
about
![Author Hilary Rosselot](https://fragilex.org/wp-content/uploads/Rosselot-Hilary-contact.jpg)
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
Summary of the Research Landscape Panel at the 18th International Fragile X Conference
Dr. Kate Shelly, a 2022 Jr. Investigator, summarizes the Research Landscape panel at the NFXF's 18th International Fragile X Conference.
Antisense Oligonucleotide (ASO) therapy being explored in Fragile X syndrome!
A publication was released this week summarizing one lab’s discovery that could lead to a future treatment for Fragile X- ASO therapy.